Literature DB >> 9990446

Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors.

V B Oza1, H M Petrassi, H E Purkey, J W Kelly.   

Abstract

Eight small molecules were synthesized to evaluate the structure activity relationships (SAR) of N-substituted anthranilic acids. The molecules were synthesized by benzylation or arylation of methyl anthranilate. A light scattering-based amyloid fibril formation assay was used to evaluate potential inhibitors of transthyretin (TTR) amyloid fibril formation in vitro. The m-carboxyphenylated and o-trifluoromethylphenylated anthranilic acids are potent inhibitors that will be subjected to further SAR and structural analysis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9990446     DOI: 10.1016/s0960-894x(98)00696-9

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  24 in total

1.  Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods.

Authors:  Richard J Nowak; Gregory D Cuny; Sungwoon Choi; Peter T Lansbury; Soumya S Ray
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

2.  A stilbene that binds selectively to transthyretin in cells and remains dark until it undergoes a chemoselective reaction to create a bright blue fluorescent conjugate.

Authors:  Sungwook Choi; Derrick Sek Tong Ong; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2010-10-21       Impact factor: 15.419

3.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.

Authors:  Christine E Bulawa; Stephen Connelly; Michael Devit; Lan Wang; Charlotte Weigel; James A Fleming; Jeff Packman; Evan T Powers; R Luke Wiseman; Theodore R Foss; Ian A Wilson; Jeffery W Kelly; Richard Labaudinière
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

4.  A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.

Authors:  Sungwook Choi; Jeffery W Kelly
Journal:  Bioorg Med Chem       Date:  2010-12-30       Impact factor: 3.641

Review 5.  Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis.

Authors:  Susan L Lindquist; Jeffery W Kelly
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-12-01       Impact factor: 10.005

Review 6.  Current and future treatment of amyloid diseases.

Authors:  M Ankarcrona; B Winblad; C Monteiro; C Fearns; E T Powers; J Johansson; G T Westermark; J Presto; B-G Ericzon; J W Kelly
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

7.  Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.

Authors:  Stephen Connelly; David E Mortenson; Sungwook Choi; Ian A Wilson; Evan T Powers; Jeffery W Kelly; Steven M Johnson
Journal:  Bioorg Med Chem Lett       Date:  2017-05-26       Impact factor: 2.823

Review 8.  The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.

Authors:  Steven M Johnson; Stephen Connelly; Colleen Fearns; Evan T Powers; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2012-01-05       Impact factor: 5.469

9.  Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.

Authors:  Steven M Johnson; Stephen Connelly; Ian A Wilson; Jeffery W Kelly
Journal:  J Med Chem       Date:  2008-09-24       Impact factor: 7.446

10.  Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors.

Authors:  Teresa Mairal; Joan Nieto; Marta Pinto; Maria Rosário Almeida; Luis Gales; Alfredo Ballesteros; José Barluenga; Juan J Pérez; Jesús T Vázquez; Nuria B Centeno; Maria Joao Saraiva; Ana M Damas; Antoni Planas; Gemma Arsequell; Gregorio Valencia
Journal:  PLoS One       Date:  2009-01-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.